{"disease":{"id":"solid-tumours","name":"solid tumours"},"drugs":{"marketed":[{"drug_id":"plerixafor","indication_name":"Solid malignant tumours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mozobil","generic_name":"plerixafor","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 2","drug_class":"Hematopoietic Stem Cell Mobilizer [EPC]","quality_score":61,"revenue":null,"mechanism":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream."},{"drug_id":"mozobil","indication_name":"Solid malignant tumours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mozobil","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04529122","title":"A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05918666","title":"National Register of Actionable Mutations","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2098,"lead_sponsor_name":"Federation of Italian Cooperative Oncology Groups","has_results":false},{"nct_id":"NCT07403370","title":"Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06304818","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":515,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT04811443","title":"DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Biocad","has_results":false},{"nct_id":"NCT06600022","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":441,"lead_sponsor_name":"Sinocelltech Ltd.","has_results":false},{"nct_id":"NCT06581432","title":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT01998607","title":"Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw","phase":"","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":403,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06888830","title":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":374,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06725758","title":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":315,"lead_sponsor_name":"Orion Corporation, Orion Pharma","has_results":false},{"nct_id":"NCT07160725","title":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":315,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06795412","title":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Pyxis Oncology, Inc","has_results":false},{"nct_id":"NCT00687622","title":"Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":206,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT07446855","title":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05154604","title":"A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":156,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT02511795","title":"AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04999969","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03518606","title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT02407509","title":"Phase I Trial of VS-6766 Alone and in Combination With Everolimus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT05701527","title":"A Study of EBC-129 in Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"EDDC (Experimental Drug Development Centre), A*STAR Research Entities","has_results":false},{"nct_id":"NCT02482311","title":"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06619509","title":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06868199","title":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"LaNova Medicines Limited","has_results":false},{"nct_id":"NCT02588105","title":"Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02093351","title":"To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00972686","title":"Dose-Escalation Study of GSK2126458","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02389842","title":"PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03421353","title":"AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03150056","title":"Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02579226","title":"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03486730","title":"BT1718 in Patients with Advanced Solid Tumours.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Cancer Research UK","has_results":false},{"nct_id":"NCT04839991","title":"Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Crescendo Biologics Ltd.","has_results":false},{"nct_id":"NCT06927349","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Shandong Boan Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT07224425","title":"A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":69,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT00732420","title":"Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT05021120","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Akesobio Australia Pty Ltd","has_results":false},{"nct_id":"NCT02610075","title":"Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02028442","title":"Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Akamis Bio","has_results":false},{"nct_id":"NCT04765462","title":"Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT01921140","title":"To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04504669","title":"First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04434482","title":"IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Impact Therapeutics, Inc.","has_results":false},{"nct_id":"NCT00483860","title":"A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01956669","title":"Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03508011","title":"A Study of IMP4297 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Impact Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02285816","title":"MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT02617277","title":"Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04564027","title":"A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}